Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 1
1970 1
1972 5
1973 1
1974 2
1975 2
1978 2
1979 3
1980 1
1981 5
1982 1
1983 3
1984 2
1985 4
1986 13
1987 6
1988 6
1989 9
1990 5
1991 13
1992 5
1993 2
1994 11
1995 11
1996 15
1997 26
1998 15
1999 14
2000 21
2001 22
2002 20
2003 23
2004 22
2005 22
2006 25
2007 24
2008 21
2009 31
2010 29
2011 20
2012 33
2013 36
2014 32
2015 45
2016 40
2017 46
2018 45
2019 51
2020 59
2021 62
2022 53
2023 45
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

928 results

Results by year

Filters applied: . Clear all
Page 1
Identification of FasL as a crucial host factor driving COVID-19 pathology and lethality.
Albert MC, Uranga-Murillo I, Arias M, De Miguel D, Peña N, Montinaro A, Varanda AB, Theobald SJ, Areso I, Saggau J, Koch M, Liccardi G, Peltzer N, Rybniker J, Hurtado-Guerrero R, Merino P, Monzón M, Badiola JJ, Reindl-Schwaighofer R, Sanz-Pamplona R, Cebollada-Solanas A, Megyesfalvi Z, Dome B, Secrier M, Hartmann B, Bergmann M, Pardo J, Walczak H. Albert MC, et al. Among authors: hartmann b. Cell Death Differ. 2024 May;31(5):544-557. doi: 10.1038/s41418-024-01278-6. Epub 2024 Mar 21. Cell Death Differ. 2024. PMID: 38514848
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.
Reimann P, Petzer V, Mündlein A, Hartmann B, Severgnini L, Winkler A, Lang T, Huynh M, Gasser K, Rüger J, Atzl M, Mink S, Fraunberger P, Schmidt S, Steiner N, Griesmacher A, Gunsilius E, Nachbaur D, Willenbacher W, Wolf D, Winder T, Benda MA. Reimann P, et al. Among authors: hartmann b. Ann Hematol. 2024 Jun;103(6):2123-2131. doi: 10.1007/s00277-024-05671-6. Epub 2024 Mar 2. Ann Hematol. 2024. PMID: 38436671
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.
Ludwig H, Melchardt T, Sormann S, Schreder M, Andel J, Hartmann B, Tinchon C, Zojer N, Gunsilius E, Podar K, Egle A, Willenbacher W, Wöll E, Ruckser R, Bozic B, Krauth MT, Petzer A, Schmitt C, Machherndl-Spandl S, Agis H, Fillitz M, Wang SY, Zabernigg A, Knop S, Paiva B, Greil R. Ludwig H, et al. Among authors: hartmann b. Am J Hematol. 2024 May;99(5):1008-1011. doi: 10.1002/ajh.27280. Epub 2024 Feb 29. Am J Hematol. 2024. PMID: 38425185 Clinical Trial.
Effects of exogenous GIP and GLP-2 on bone turnover in individuals with type 2 diabetes.
Skov-Jeppesen K, Christiansen CB, Hansen LS, Windeløv JA, Hedbäck N, Gasbjerg LS, Hindsø M, Svane MS, Madsbad S, Holst JJ, Rosenkilde MM, Hartmann B. Skov-Jeppesen K, et al. Among authors: hartmann b. J Clin Endocrinol Metab. 2024 Jan 13:dgae022. doi: 10.1210/clinem/dgae022. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 38217866
928 results